Management of thrombocytopenia in advanced liver disease

被引：51

作者：

Gangireddy, V. G. R. ^{[1
]}

Kanneganti, P. C. ^{[2
]}

Sridhar, S. ^{[1
]}

Talla, S. ^{[3
]}

Coleman, T. ^{[4
]}

机构：

[1] Georgia Regents Univ, Augusta, GA 30912 USA

[2] Helena Reg Med Ctr, Helena, AR USA

[3] Luzhou Med Coll, Luzhou, Peoples R China

[4] Archbold Med Ctr, Thomasville, GA USA

来源：

CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2014年 / 28卷 / 10期

关键词：

Advanced liver disease; Cirrhosis; Splenectomy; Splenic artery embolization; Thrombocytopenia; Thrombopoietin stmulators; PARTIAL SPLENIC EMBOLIZATION; HEPATITIS-C VIRUS; PORTAL-VEIN THROMBOSIS; INTRAHEPATIC PORTOSYSTEMIC SHUNT; SERUM THROMBOPOIETIN LEVELS; STEM-CELL TRANSPLANTATION; PLATELET-ASSOCIATED IGG; LAPAROSCOPIC SPLENECTOMY; CIRRHOTIC-PATIENTS; RADIOFREQUENCY ABLATION;

D O I：

10.1155/2014/532191

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Thrombocytopenia (defined as a platelet count <150x10(9)/L) is a wellknown complication in patients with liver cirrhosis and has been observed in 76% to 85% of patients. Significant thrombocytopenia (platelet count <50x10(9)/L to 75x10(9)/L) occurs in approximately 13% of patients with cirrhosis. Thrombocytopenia can negatively impact the care of patients with severe liver disease by potentially interfering with diagnostic and therapeutic procedures. Multiple factors can contribute to the development of thrombocytopenia including splenic platelet sequestration, immunological processes, bone marrow suppression by chronic viral infection, and reduced levels or activity of the hematopoietic growth factor thrombopoietin. The present review focuses on the etiologies and management options for severe thrombocytopenia in the setting of advanced liver disease.

引用

页码：558 / 564

页数：7

共 92 条

[31] Reduced expression of thrombopoietin is involved in thrombocytopenia in human and rat liver cirrhosis [J].